Prostate adenocarcinoma is the most common malignancy diagnosed in males, and bone metastases remain a significant source of morbidity and mortality in this population. The ubiquitin-proteasome cascade is responsible for the degradation of intracellular proteins, and this pathway is thought to play an essential role in the development of malignancies by altering the levels of various proteins involved in the regulation of cell division. Proteasome inhibitors represent a class of chemotherapeutic agents that have been shown to inhibit tumor growth by a number of different mechanisms. Using a murine intratibial injection model, we examined the effects of the proteasome inhibitor bortezomib on the establishment and progression of osteolytic bone lesions induced by human CaP cells (PC-3 cell line). In this study, the intravenous administration of bortezomib (1 mg/kg) did not prevent the initial formation of osteolytic lesions but did appear to inhibit their growth in a time-dependent fashion. In contrast, bortezomib therapy effectively inhibited the establishment and progression of subcutaneous PC-3 tumors, which served as a positive control. These results suggest that proteasome inhibitors such as bortezomib may represent a novel adjunctive therapy for the treatment of osteolytic skeletal metastases, especially when treatment is initiated early during the disease process.
Introduction
According to the American Cancer Society, prostate adenocarcinoma (CaP) is the most common malignancy occurring in men, accounting for one-third of all new diagnoses of cancer made in male patients. 1 CaP is also a major cause of cancer death among males, second only to lung cancer in the United States. Based on these data, it has been estimated that over 220 000 men will be diagnosed with CaP this year and almost 30 000 will die from this disease. CaP preferentially metastasizes to bone, a tissue that appears to be conducive to the growth and survival of CaP cells. 2 Much of the morbidity associated with CaP, including unremitting pain and pathologic fractures, is related to the development of metastatic skeletal lesions that may be present in up to 80% of cases. 3, 4 Moreover, the 5-year survival rate among CaP patients with bony metastases continues to be less than 50%. 5 The ubiquitin-proteasome system represents the primary pathway for the elimination of intracellular proteins in all eukaryotic cells. Proteins targeted for destruction are marked with a polyubiquitin chain and directed toward the proteasome, a large, multisubunit protease that rapidly degrades these proteins into smaller peptides. 6, 7 The ubiquitin-proteasome pathway is essential to cellular homeostasis and is considered to be an important regulator of multiple metabolic processes such as osteoblast differentiation and bone formation. 8 In addition to removing damaged and other abnormal proteins from the cell, proteasome-mediated proteolysis also facilitates the coordinated degradation of numerous proteins that are involved in cellular proliferation and apoptosis. By controlling the levels of numerous transcription factors, tumor suppressors, anti-apoptotic proteins, and other signaling molecules, the proteasome has been shown to be vital for cell cycle progression as well as programmed cell death. [9] [10] [11] However, anomalous proteasomal activity resulting in the disordered degradation of these cell cycle regulatory proteins has also been implicated in neoplastic growth and tumor metastasis. 12 Since its critical role in the establishment and propagation of malignancies, the proteasome has recently been identified as a potential target for newer chemotherapeutic agents. Proteasome inhibitors have exhibited cytotoxicity against a wide range of tumor cell lines, and these drugs are thought to impede tumor growth by several different mechanisms. By limiting the degradation of various cell cycle regulatory proteins, proteasome inhibitors may induce mitotic arrest and apoptosis. [13] [14] [15] The potent antiangiogenic effects of proteasome inhibitors is well documented, and these agents have been shown to prevent tumor cell neovascularization in both in vitro and in vivo studies. [14] [15] [16] [17] [18] [19] Suppression of proteasome function may also disrupt the NF-kB signal transduction cascade that is known to be active in a variety of different malignancies. 20, 21 NF-kB is a transcription factor that stimulates the production of inflammatory mediators, adhesion molecules, and antiapoptotic proteins that promote tumor proliferation, metastasis, and chemoresistance. [22] [23] [24] Initiation of the NF-kB signaling pathway is dependent upon the ubiquitin-proteasome system, which facilitates the degradation of its inhibitory protein, IkB. 25, 26 By stabilizing the inhibitory protein of NF-kB, proteasome inhibitors may block NF-kB-mediated transcription in tumor cells and enhance their susceptibility to antineoplastic drugs and radiation therapy. [27] [28] [29] [30] [31] Proteasome inhibitors also demonstrate relatively greater toxicity against transformed cells, which may be more sensitive to proteasome dysfunction than normal, nonmalignant cells. 27, 29, 32 Bortezomib (formerly known as PS-341) is a dipeptidyl boronic acid compound that acts as an extremely potent and selective proteasome inhibitor. By blocking the ubiquitin-proteasome pathway, bortezomib may prevent the degradation of multiple regulatory proteins and transcription factors that are involved in cell division, apoptosis, cellular adhesion, angiogenesis, and NF-kB activation, ultimately leading to the arrest of tumor growth and metastasis. Bortezomib's proposed mechanism of action has been found to be unique compared to the cytotoxic profiles of over 60 000 agents present in the NCI anticancer drug database. 13 Like other proteasome inhibitors, bortezomib also appears to be more lethal to malignant cells than normal cells, and this drug may be particularly effective for the treatment of tumors that are resistant to conventional chemotherapeutic regimens. 15, 33 Bortezomib is the first proteasome inhibitor to be tested in humans and this agent is currently being evaluated in a number of clinical trials involving a variety of hematologic and solid malignancies. [34] [35] [36] Since the promising results of a Phase II study assessing the efficacy of bortezomib in patients with multiple myeloma, this drug has already entered Phase III trials and has also received accelerated approval from the US Food and Drug Administration (FDA) for the treatment of progressive disease refractory to prior therapies. 37, 38 A Phase I clinical trial that included patients with androgen-independent CaP was recently completed in order to determine the pharmacokinectics and pharmacodynamics of intravenous bortezomib, establish the maximum-tolerated dose and dose-limiting toxicity of this regimen, and confirm its deleterious effects against CaP cells.
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According to the NCI's in vitro antineoplastic screening panel consisting of 60 human cancer cell lines, bortezomib demonstrates tumoricidal activity against a number of malignancies, including CaP. 13 Bortezomib has also been shown to arrest cell cycle progression and induce apoptosis in cultured human CaP cells as well as inhibit the growth of CaP tumor xenografts in a murine model. 13, 40 In one study, nude mice implanted with CaP PC-3 cells experienced a 60% decrease in tumor burden following weekly intravenous bortezomib therapy; when directly injected into PC-3 xenografts, bortezomib generated an even larger decrease in tumor volume. 13 Bortezomib has successfully been used to augment the radiosensitivity of CaP cells and circumvent multicellular drug resistance in slow-growing CaP tumors. 33 In addition to their antiangiogenic and direct cytotoxic effects, bortezomib and other proteasome inhibitors may also block androgen-dependent CaP growth. 41 Collectively, these preclinical reports suggest that proteasome inhibitors such as bortezomib are a novel class of chemotherapeutic agents that are active against CaP and other solid tumors. Based on these findings, proteasome inhibitors may also represent a potential treatment for skeletal metastases associated with osteolysis. The purpose of the present study was to determine the effects of bortezomib on the establishment and progression of osteolytic bone lesions induced by human CaP cells using a murine bone metastasis model.
Methods

Cell culture
The human prostate cancer cell line PC-3 (American Type Culture Collection) was used in this study. PC-3 cells generate purely osteolytic lesions when implanted into bone. 42, 43 Cell culture reagents were obtained from Gibco/Life Technologies (Rockville, MD, USA) unless otherwise specified. PC-3 cells were cultured in Iscove's medium (Irvine Scientific, Irvine, CA, USA) supplemented with 15% FBS and 1% glutamine. Cells were maintained at 371C in a humidified incubator with 5% CO 2 .
Animal care
Severe combined immunodeficient (SCID) male mice (8-week-old) were housed under pathogen-free conditions according to a protocol approved by the Chancellor's Animal Research Committee at the primary institution.
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Suspension of PC-3 cells
SCID mice with subcutaneous (SC) PC-3 tumors were anesthetized with 100 mg ketamine and 10 mg xylazine/kg body weight prior to their sacrifice. The skin overlying the tumors was shaved and prepped with 70% ethanol and Betadine. The tumor was sterilely explanted and minced in PBS (Invitrogen Life Technologies, Carlsbad, CA, USA) with a sterile razor blade. The slurry was transferred to a sterile 50 ml conical tube (Becton Dickson Labware, Franklin Lakes, NJ, USA) and spun in a centrifuge (1300 r.p.m.) for 5 min at room temperature. The supernatant was aspirated, and the remaining pellet was resuspended in Iscove's medium. The resultant slurry was again centrifuged for 5 min at room temperature. After the supernatant was aspirated, the pellet was resuspended in a filtered 0.1% Pronase E/Iscove's medium solution. This cell suspension was shaken on a rotating platform for 18 min at room temperature and then placed on ice for 2 min. The cell suspension was passed through a 70 mm cell strainer (Becton Dickson Labware) and centrifuged for 5 min at room temperature. The supernatant was aspirated and the pellet was resuspended in Iscove's medium supplemented with 15% FBS and 1% glutamine. The PC-3 cells were plated in 10 ml culture dishes (Becton Dickson Labware) and 1 Â fungizone (Invitrogen Life Technologies) was added to all of the plates. The plates were incubated at 371C in a humidified incubator with 5% CO 2 until the time of tibial injection.
Tibial implantation of PC-3 cells
PC-3 cells were combined with an equal amount of Matrigel (Collaborative Biomedical Products, Bedford, MA, USA) to generate single-cell suspensions consisting of 1 Â 10 5 in 10 ml of solution. Male 8-week-old SCID mice were anesthetized with 100 mg ketamine and 10 mg xylazine/kg body weight. The skin overlying their left hind limbs was shaved and prepped in a sterile fashion with 70% ethanol and Betadine. A no. 15 scapel blade was used to make a 3 mm longitudinal skin incision over the patella and a 2 mm incision along the medial aspect of the patellar ligament. The knee was flexed to 901 and a 0.5 in 27 gauge needle was inserted through the tibial plateau. The single-cell suspension (1 Â 10 5 PC-3 cells in 10 ml) was then injected into the proximal tibia. The skin incision was closed using a 5-0 Vicryl suture (Ethicon Inc., Somerville, NJ, USA). All animals were killed 8 weeks after tibial implantation.
SC implantation of PC-3 cells
As with tibial implantation, single-cell suspensions of PC-3 cells were combined with an equal amount of Matrigel so that 1 Â 10 6 cells were present in a total volume of 50 ml. Male 8-week-old SCID mice were anesthetized (100 mg ketamine and 10 mg xylazine/kg body weight) and their left flanks were shaved and prepped with 70% ethanol and Betadine. The single-cell suspension (1 Â 10 6 PC-3 cells in 50 ml) was then injected subcutaneously into the left flank of each mouse. Animals were examined for palpable SC tumors on a weekly basis. All animals were killed 8 weeks after injection at which time the dimensions of each palpable SC tumor were determined using calipers.
Intratibial tumor treatment protocols
Male 8-week-old SCID mice that underwent tibial implantation with PC-3 cells were treated with intravenous bortezomib (1.0 mg/kg body weight; Millennium Pharmaceuticals Inc., Cambridge, MA, USA) according to the following treatment protocols (see Figure 1) .
Protocol 1: Effects of prophylactic treatment on intratibial PC-3 tumors (pretreatment group, n ¼ 8). Bortezomib was administered twice a week starting 1 week prior to tibial implantation and was continued for another 4 weeks after tibial implantation, for a total of 5 weeks of treatment.
Protocol 2: Effects of interventional treatment on intratibial PC-3 tumors (weekly treatment group, n ¼ 8). Bortezomib was administered twice a week starting on the day of tibial implantation and was continued for a total of 4 weeks of treatment.
Protocol 3: Effects of treatment on established intratibial PC-3 tumors (delayed treatment group, n ¼ 8). Bortezomib was administered twice a week starting 4 weeks after tibial implantation and was continued for a total of 4 weeks of treatment.
Protocol 4: Intratibial controls (n ¼ 8). Saline was administered intravenously twice a week starting on the day of tibial implantation and was continued for a total of 4 weeks. 
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SC tumor treatment protocols
Male 8-week-old SCID mice that underwent SC implantation of PC-3 cells were treated with intravenous bortezomib (1 mg/kg body weight) according to the following treatment protocols (see Figure 1 ). Protocol 5: Effects of interventional treatment on SC PC-3 tumors (SC weekly treatment group, n ¼ 5). Bortezomib was administered twice a week starting on the day of SC implantation and was continued for a total of 4 weeks of treatment.
Protocol 6: Effects of treatment on established SC PC-3 tumors (SC delayed treatment group, n ¼ 5). Bortezomib was administered twice a week starting 4 weeks after SC implantation and was continued for a total of 4 weeks of treatment.
Protocol 7: SC controls (n ¼ 5). Saline was administered intravenously twice a week starting on the day of SC implantation and was continued for a total of 4 weeks.
Radiographic analysis
Prior to their sacrifice, all animals that had undergone tibial implantation of PC-3 cells were anesthetized (100 mg ketamine and 10 mg xylazine/kg body weight) and radiographs were obtained of each animal (Faxitron, Field Emission Corp., McMinniville, OR, USA). Radiographic evidence of osteolytic bone destruction was quantified using a grading system based upon the extent of cortical bone loss noted in each tibia (Table 1) . Radiographs were scored by three different readers in a blinded fashion.
Histology and histomorphometric analysis
At the time of sacrifice, both tibias of each SCID mouse that had undergone tibial implantation of PC-3 cells were harvested for histological analysis according to a previously established protocol. 44,45. The tibias were initially fixed in 10% buffered formalin and decalcified in 10% EDTA. The specimens were then placed on a rotating platform for 2 weeks at room temperature. The tibias were embedded in paraffin, and 3 mm sections were obtained along the midsaggital plane. The sections were stained with hemotoxylin and eosin (H&E), Orange G, and tartrate resistant acid phosphatase (TRAP); Orange G is a stain that is specific for bone formation and TRAP staining is used to identify osteoclast activity. Histologic evidence of osteolytic bone destruction was quantified according to the same grading system used to evaluate the radiographs, based upon the degree of cortical disruption observed in each tibia (Table 1) . Specimens were again scored by three different readers in a blinded fashion.
Histomorphometric analysis was also performed on these histologic sections (Olympus, Melville, NY, USA). Osteoclast number was calculated by examining histologic specimens for TRAP-positive cells present in bone. The area of bone present in each tibia was determined using BIOQUANT software (BIOQUANT Image Analysis Corp., Nashville, TN, USA).
Statistical analysis
Statistical calculations were performed using Stata software, version 7.0. (Stata Corp., College Station, TX, USA). P-values less than or equal to 0.05 were considered to be statistically significant. The radiographic and histologic scores were analyzed using one-way ANOVA with the Sidak multiple comparison procedure and k statistics were generated to determine interobserver agreement. 46 The histomorphometric data were subjected to statistical analysis using the Kruskall-Wallis nonparametric rank test (osteoclast number) and one-way ANOVA with the Sidak multiple comparison procedure (bone area). The mean SC tumor volumes were evaluated using the Student's t-test.
Results
Bortezomib does not prevent the formation of osteolytic prostate cancer bone tumors but inhibits their subsequent growth
In order to determine its efficacy in limiting the establishment and progression of osteolytic CaP bone lesions, intravenous bortezomib was administered to SCID mice that had undergone tibial implantation of PC-3 cells according to the Pretreatment, Weekly Treatment and Delayed Treatment protocols (see Methods). Radiographs of these animals that were obtained at the time of sacrifice were graded by three different readers in a blinded fashion (k ¼ 0.59) and given a radiographic score based upon the extent of cortical bone loss noted on each X-ray ( Table 1 ). All of the PC-3-implanted tibias demonstrated radiographic evidence of osteolysis characteristic of PC-3 lesions. In the intratibial Control group animals, there was extensive bony destruction with almost complete obliteration of the proximal tibia Complete destruction of the proximal tibia Table 2 ). In the bortezomib-treated groups, the radiographic appearance of the osteolytic lesions improved with the earlier administration of bortezomib; however, the differences between the radiographic scores of the Pretreatment, Weekly Treatment and Delayed Treatment groups were not statistically significant. Histologic sections of all the PC-3-implanted tibias were stained with H&E and Orange G in order to assess both the magnitude of tumor cell burden and the extent of osteolytic bone loss present in these tibias. Similar to the evaluation of the radiographs, these specimens were also scored by three different readers in a blinded fashion (k ¼ 0.64) according to an identical grading scale based upon the degree of cortical disruption (Table 1) . Histologic analysis of the Control and bortezomib-treated groups confirmed the presence of osteolytic bone lesions in all of the sections. In the Control and Delayed treatment groups, each tibial specimen demonstrated a large mass of tumor cells proximally with essentially no cortical bone remaining between the femur and distal portion of the tibia (Figure 3a and b) . Although tumor cells were still apparent, the histologic sections obtained from the Weekly Treatment group were determined to have significantly less cortical bone loss than those of the Control and Delayed Treatment groups (Po0.001; Figure 3c and Table 2 ). The osteolytic lesions evident in the Pretreatment tibias were associated with greater cortical integrity and smaller tumor burdens, and the mean histologic score of this group was significantly less than those of all of the other groups (Po0.05; Figure 3d ).
Histomorphometric analysis of cortical bone area was also performed on the histologic specimens in an attempt to quantify the amount of osteolytic bone loss present in these PC-3-implanted tibias ( Table 2 ). There was significantly less bone destruction in the Weekly Treatment group sections relative to those of the Control and Delayed Treatment groups (Po0.05). The greatest mean residual bone area was observed in the Pretreatment tibias, which was significantly greater than the values of all the other groups (Po0.005). Histologic sections were 
Discussion
CaP metastases to bone represent a significant source of morbidity and mortality, resulting in a number of clinical complications including pain, fractures, and compression of the spinal cord. 3, 4 Although CaP tumors generally exhibit an osteoblastic phenotype, it is believed that these metastases are at least in some part dependent upon an osteolytic process that facilitates their propagation within bone. 44, 45, 47, 48 By injecting human CaP cells into the tibiae of SCID mice, our laboratory has developed an in vivo model that consistently yields osteolytic lesions. 44, 45 Using this model, it is possible to determine the effects of a therapeutic agent such as bortezomib on the formation of osteolytic metastases to bone. The present study was designed to evaluate the efficacy of bortezomib in limiting the establishment and progression of osteolytic bone lesions induced by these human CaP cells.
In our experiments, the intravenous administration of bortezomib did not prevent the formation of osteolytic lesions in any of the tibias implanted with PC-3 cells. Radiographs obtained at the time of sacrifice showed that all of the animals in the four intratibial tumor groups (Pretreatment, Weekly Treatment, Delayed Treatment, and Controls) exhibited osteolytic changes in the proximal tibia characteristic of PC-3 bony tumors. The presence of osteolytic lesions in all of these animals was confirmed by histologic examination, which demonstrated cortical bone loss and tumor cell masses in each of the tibial specimens.
Although treatment with bortezomib did not preclude the initial development of these lesions, it did appear to inhibit their subsequent growth within bone. While the radiographs of the intratibial Control group animals revealed extensive osteolysis that extended throughout the entire proximal tibia, those taken of the animals that had received bortezomib displayed less bony destruction with greater preservation of tibial anatomy, findings that were reflected in their radiographic scores. The mean radiographic scores of the Pretreatment, Weekly Treatment, and Delayed Treatment groups were all significantly lower than that of the control group. Similarly, histologic and histomorphometric analyses of the tibias also suggested that bortezomib therapy limited the growth of these osteolytic CaP lesions. In each of the Control specimens, there was nearly complete eradication of the proximal tibia, which was replaced with large collections of tumor cells. However, the histologic sections prepared from Pretreatment and Weekly Treatment tibias displayed less cortical bone loss and smaller tumor burdens, and the mean histologic scores and residual bone areas of these groups were significantly improved compared to the values of the Control group.
In this model, the efficacy of bortezomib was clearly influenced by the time at which the drug was first administered. The Pretreatment and Weekly Treatment groups that received bortezomib early before disease progression had occurred exhibited significantly better mean histologic scores and residual bone area values than the Delayed Treatment group, with the greatest histologic and histomorphometric improvements observed amongst the Pretreatment animals that began bortezomib therapy one week prior to CaP cell implantation. A time-dependent trend towards improved radiographic scores was also evident in the bortezomib groups according to when treatment was initiated, but these differences were not statistically significant. This association between the timing of bortezomib therapy and the subsequent growth of osseous CaP lesions suggests that the earlier bortezomib is administered, the more effective it will be as a treatment for CaP metastases to bone. Thus, in clinical situations involving patients with CaP, bortezomib therapy may prove to be more beneficial if it is started prior to the establishment of bony metastases.
Abnormal regulation of the ubiquitin-proteasome system has previously been implicated in the pathologic processes of malignant growth and tumor metastasis, and these findings have served as the rationale for the use of proteasome inhibitors as adjuvant therapies for a variety of neoplasms. 12, 13 A number of preclinical studies have proven bortezomib and other proteasome inhibitors to be particularly effective against CaP tumors, and it is likely that these substances promote CaP cell death by several different mechanisms including induction of apoptosis and mitotic arrest, inhibition of angiogenesis, blockade of the NF-kB signal transduction cascade, and suppression of androgen receptor-dependent growth. 13, 40, 41 Bortezomib has even been shown to overcome multicellular drug resistance in CaP cell lines with low growth fractions and increase the sensitivity of CaP tumors to radiation therapy. 33 The proposed role of osteoclast-mediated bone resorption in the development of skeletal metastases has served as the rationale for the use of osteoclast antagonists such as the bisphosphonates as potential adjuvant therapies for a number of different malignancies including CaP. 44, [47] [48] [49] [50] Using this same intratibial injection model, our laboratory previously reported that PC-3 cells did not form osseous lesions in animals that were treated with the bisphosphonate zoledronate. 44 Since there were
Effects of the proteasome inhibitor bortezomib PG Whang et al fewer osteoclasts noted in the zoledronate-treated groups, it was hypothesized that the inhibition of osteolytic tumor formation may have occurred as a result of this reduction in osteoclast activity. In the present study, histomorphometric analysis of osteoclast number did not demonstrate any differences between the bortezomib-treated tibias and the Control group specimens, confirming that the mechanism of action of bortezomib is distinct from that of anti-osteoclast agents in that it does not affect osteoclast differentiation or function but more likely has a direct cytotoxic effect upon malignant cells. In addition to its effects on the progression of osteolytic CaP tumors, bortezomib also successfully prevented the development of de novo SC CaP lesions in SCID mice. During the entire period of observation there were no palpable SC tumors identified among any of the SC Weekly Treatment animals that started bortezomib treatment immediately following the SC implantation of PC-3 cells. The administration of bortezomib also appeared to impede the progression of established SC lesions; following the completion of bortezomib therapy, the mean SC tumor volume of the SC Delayed Treatment group was significantly less than that of the SC Control group. These findings are corroborated by a similar investigation performed by Adams et al 13 , who also found that an identical dose of intravenous bortezomib (1.0 mg/kg) produced a comparable decrease in the volume of established SC tumors in SCID mice implanted with PC-3 cells. Collectively, these experiments serve to confirm the potent tumoricidal effects of bortezomib against CaP cells in this particular environment.
In this study, bortezomib more effectively inhibited the growth and development of SC PC-3 tumors than similar lesions in bone. The exact mechanisms underlying the decreased susceptibility of intratibial CaP lesions to bortezomib therapy remain unknown; however, it appears as if bone provides an environment for CaP cells that confers at least partial resistance to this agent, at least compared to other tissue types. One possibility for the poorer response of intratibial PC-3 tumors to bortezomib treatments may be the relatively diminished vascularity of bone compared to the SC tissues, resulting in reduced drug bioavailability and ultimately less tumoricidal activity against CaP cells present in bone. Adams et al 13 used radiolabeled compounds in conjunction with autoradiography to evaluate the pharmacokinetic and pharmacodynamic profiles of bortezomib in rats. Since only minimal levels of bortezomib were detected in the skin and bone marrow, it is likely that the penetration of this drug into both of these tissues is quite low. Although Adams et al 13 determined that less than 1% of the administered bortezomib was actually distributed to SC PC-3 tumors, even this limited exposure to bortezomib was potent enough to significantly inhibit proteasome activity and decrease tumor cell burden. However, the direct administration of bortezomib into SC PC-3 tumors produced almost complete regression of these lesions, suggesting that the efficacy of bortezomib may be dependent upon its bioavailability within the tissue of interest. Additional studies are necessary to better characterize the therapeutic effects of bortezomib on the behavior of skeletal metastases and identify the various factors that may influence its ability to penetrate bone and other tissues.
Based on its documented tumoricidal effects against a number of different malignancies in preclinical experiments, bortezomib was the first proteasome inhibitor entered into clinical trials including patients with a variety of solid and hematologic tumor types. [34] [35] [36] [37] Bortezomib has recently gained US FDA approval for the treatment of multiple myeloma resistant to other therapies, and its efficacy in this patient population is currently being evaluated in a Phase III study. 38 The safety profile of intravenous bortezomib has already been assessed in a Phase I trial that included subjects with androgen-independent CaP, and in these patients bortezomib demonstrated antitumor activity at doses that were well tolerated. 39 In summary, we found that the proteasome inhibitor bortezomib did not prevent the formation of osteolytic CaP bone lesions but did limit their subsequent growth. Bortezomib also successfully inhibited the development of SC CaP tumors. Because of its cytotoxic activity against CaP cells and other tumors, bortezomib may represent a novel adjunctive therapy for bone metastases that may prove to be more effective the earlier treatment is initiated. Clinical trials are already underway to assess the safety and efficacy of proteasome inhibitors for the treatment of CaP and other malignancies.
